» Articles » PMID: 16185723

Serotonin-transporter Mediated Efflux: a Pharmacological Analysis of Amphetamines and Non-amphetamines

Overview
Specialties Neurology
Pharmacology
Date 2005 Sep 28
PMID 16185723
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

The physiological function of neurotransmitter transporter proteins like the serotonin transporter (SERT) is reuptake of neurotransmitter that terminates synaptic serotoninergic transmission. SERT can operate in reverse direction and be induced by SERT substrates including 5-HT, tyramine and the positively charged methyl-phenylpyridinium (MPP(+)), as well as the amphetamine derivatives para-chloroamphetamine (pCA) and methylene-dioxy-methamphetamine (MDMA). These substrates also induce inwardly directed sodium currents that are predominantly carried by sodium ions. Efflux via SERT depends on this sodium flux that is believed to be a prerequisite for outward transport. However, in recent studies, it has been suggested that substrates may be distinct in their properties to induce efflux. Therefore, the aim of the present study was a pharmacological characterization of different SERT substrates in uptake experiments, their abilities to induce transporter-mediated efflux and currents. In conclusion, the rank order of affinities in uptake and electrophysiological experiments correlate well, while the potencies of the amphetamine derivatives for the induction of efflux are clearly higher than those of the other substrates. These discrepancies can be only explained by mechanisms that can be induced by amphetamines. Therefore, based on our pharmacological observations, we conclude that amphetamines distinctly differ from non-amphetamine SERT substrates.

Citing Articles

5-HT_FAsTR: a versatile, label-free, high-throughput, fluorescence-based microplate assay to quantify serotonin transport and release.

Bukowski L, Strom M, Andersen J, Maesen J, Tian L, Sinning S Sci Rep. 2024; 14(1):6541.

PMID: 38504103 PMC: 10951269. DOI: 10.1038/s41598-024-56712-z.


Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties.

Puigseslloses P, Nadal-Gratacos N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R Mol Psychiatry. 2024; 29(8):2346-2358.

PMID: 38486047 PMC: 11412900. DOI: 10.1038/s41380-024-02506-8.


Ligand coupling mechanism of the human serotonin transporter differentiates substrates from inhibitors.

Gradisch R, Schlogl K, Lazzarin E, Niello M, Maier J, Mayer F Nat Commun. 2024; 15(1):417.

PMID: 38195746 PMC: 10776687. DOI: 10.1038/s41467-023-44637-6.


Development and validation of an automated microfluidic perfusion platform for parallelized screening of compounds in vitro.

Brugnoli F, Holy M, Niello M, Maier J, Hanreich M, Menzel M Basic Clin Pharmacol Toxicol. 2023; 133(5):535-547.

PMID: 37658634 PMC: 10952622. DOI: 10.1111/bcpt.13940.


Serotonin system in the human placenta - the knowns and unknowns.

Peric M, Beceheli I, cicin-Sain L, Desoye G, Stefulj J Front Endocrinol (Lausanne). 2022; 13:1061317.

PMID: 36531448 PMC: 9751904. DOI: 10.3389/fendo.2022.1061317.